New TB prevention dosing study aims to protect children from active disease
NCT ID NCT03730181
First seen May 08, 2026 · Last updated May 25, 2026 · Updated 4 times
Summary
This study tested two medicines, rifapentine and isoniazid, to prevent active tuberculosis (TB) in children up to 12 years old who had latent (hidden) TB infection. The goal was to find the safest and most effective dose for both HIV-infected and HIV-uninfected children. Researchers measured drug levels in the blood and monitored for side effects to create a dosing guide for pediatric use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATENT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Desmond Tutu TB Center, University of Stellenbosch
Stellenbosch, South Africa
Conditions
Explore the condition pages connected to this study.